Document Detail


Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial.
MedLine Citation:
PMID:  18346060     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Neuropathic pain associated with postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (DPN) can be intractable and may not respond to commonly used treatments, such as tricyclic antidepressants (TCAs) and opioids. This long-term, open-label study was a preliminary evaluation of pregabalin for patients whose pain had been judged refractory to other treatments for neuropathic pain.
DESIGN: Patients had previously participated in double-blind, placebo-controlled, randomized trials of pregabalin in DPN and PHN. They had moderate to severe neuropathic pain despite treatment with gabapentin, a TCA, and a third medication (e.g., other anticonvulsants, opioid, selective serotonin reuptake inhibitor, tramadol). Flexible-dosage pregabalin 150-600 mg/day was taken for 3-month periods followed by 3- to 28-day pregabalin "drug holidays," with an analysis up to 15 months (five treatment cycles). Pain intensity was measured using the visual analog scale of the Short-Form McGill Pain Questionnaire.
RESULTS: In total, 81 patients were included in this analysis. Pregabalin 150-600 mg/day was associated with clinically meaningful and sustained pain reduction during each treatment cycle. During pregabalin "drug holidays," pain quickly returned to baseline levels; it was reduced again when pregabalin was reinstated.
CONCLUSIONS: These results suggest that pregabalin may be beneficial in patients with neuropathic pain who have had an unsatisfactory response to treatment with other medications.
Authors:
Brett R Stacey; Robert H Dworkin; Kevin Murphy; Uma Sharma; Birol Emir; Teresa Griesing
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-03-11
Journal Detail:
Title:  Pain medicine (Malden, Mass.)     Volume:  9     ISSN:  1526-4637     ISO Abbreviation:  Pain Med     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-12-10     Completed Date:  2009-02-12     Revised Date:  2013-08-21    
Medline Journal Info:
Nlm Unique ID:  100894201     Medline TA:  Pain Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1202-8     Citation Subset:  IM    
Affiliation:
Department of Comprehensive Pain Center, Anesthesiology and Peri-Operative Medicine, Oregon Health & Science University, Portland, Oregon 97239, USA. staceyb@ohsu.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Analgesics / therapeutic use*
Diabetic Neuropathies / complications
Double-Blind Method
Humans
Neuralgia / drug therapy*,  etiology
Neuralgia, Postherpetic / complications
Pain Measurement
Pain, Intractable / drug therapy*,  etiology
Placebos
Questionnaires
Randomized Controlled Trials as Topic
Treatment Outcome
gamma-Aminobutyric Acid / analogs & derivatives*,  therapeutic use
Chemical
Reg. No./Substance:
0/Analgesics; 0/Placebos; 55JG375S6M/pregabalin; 56-12-2/gamma-Aminobutyric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Oral ketamine for pain relief in a child with abdominal malignancy.
Next Document:  Using evidence in pain practice: Part II: Interpreting and applying systematic reviews and clinical ...